Drug index
Jump to navigation
Jump to search
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
- ASCO-ONS Standards for Safe Chemotherapy Administration
- Chemotherapy Administration Sequence[2] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- FDA drug shortages list
- Steroid conversions
- Vesicant & irritant chemotherapy
A
- Abiraterone (Zytiga)
- Acyclovir (Zovirax)
- Ado-trastuzumab emtansine (Kadcyla) FDA approved 2/22/2013
- Afatinib (BIBW 2992) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN8237) in clinical trials
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- Amatuximab (MORAb-009) in clinical trials
- AMG 386 in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin (ATG)
- Apixaban (Eliquis) FDA approved 12/28/2012
- Argatroban
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Aspirin
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG)
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bivalirudin (Angiomax)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- Bleomycin (Blenoxane)
- Blinatumomab (MT103) in clinical trials
- Bortezomib (Velcade)
- Bosutinib (Bosulif) FDA approved 9/4/2012
- Brentuximab vedotin (Adcetris)
- Brivanib (BMS-582664) in clinical trials
- Buparlisib (BKM120) in clinical trials
- Busulfan (Myleran)
C
- Cabazitaxel (Jevtana)
- Cabozantinib (Cometriq) FDA approved 11/29/2012
- CAL-101 in clinical trials
- Calcium phosphate rinse (Caphosol)
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis) FDA approved 7/20/2012
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- CAT-3888 (BL22) in clinical trials
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clodronate (Bonefos)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Crizotinib (Xalkori)
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dabrafenib (GSK2118436) in clinical trials
- Dacarbazine (DTIC)
- Dacomitinib (PF-00299804) in clinical trials
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- DMUC5754A MMAE in clinical trials
- DN24-02 in clinical trials
- Docetaxel (Taxotere)
- Dovitinib (TKI-258) in clinical trials
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Enoxaparin (Lovenox)
- Entinostat in clinical trials
- Enzalutamide (Xtandi) FDA approved 8/31/2012
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor IX complex (Profilnine)
- Factor XIII concentrate, human (Corifact)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Fulvestrant (Faslodex)
G
- Galeterone (TOK-001) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord)
- Heparin
- HER2 peptide vaccine (AE37) in clinical trials
- Hydroxyurea (Hydrea)
I
- Ibandronate (Boniva)
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (PCI-32765) in clinical trials
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Inotuzumab ozogamicin (CMC-544) in clinical trials
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Ixabepilone (Ixempra)
- Ixazomib (MLN9708) in clinical trials
L
- Lapatinib (Tykerb)
- Lenalidomide (Revlimid)
- Lepirudin (Refludan)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Linifanib (ABT-869) in clinical trials
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (HA22) in clinical trials
- MPDL3280A in clinical trials
- Mycophenolate mofetil (CellCept)
N
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- NovoTTF-100A device
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Odanacatib (MK-0822) in clinical trials
- ODM-201 in clinical trials
- Ofatumumab (Arzerra)
- Olaparib (AZD-2281) in clinical trials
- Omacetaxine (Synribo) FDA approved 10/26/2012
- Ombrabulin (AVE8062) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Oprelvekin (Neumega)
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Palbociclib (PD-0332991) in clinical trials
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (LBH589) in clinical trials
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta) FDA approved 6/8/2012
- Phosphomannopentaose sulfate (PI-88) in clinical trials
- Phytonadione (Vitamin K)
- Pixantrone (BBR 2778) in clinical trials
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Pomalyst) FDA approved 2/8/2013
- Ponatinib (Iclusig) FDA approved 12/14/2012
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Protamine sulfate
R
- Radium-223 (Alpharadin) in clinical trials
- Raloxifene (Evista)
- Ramucirumab (IMC-1121B) in clinical trials
- Regorafenib (Stivarga) FDA approved 9/27/2012
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Risedronate (Actonel)
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto)
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi)
S
- S-1 in clinical trials
- Samarium-153 (Quadramet)
- Sapacitabine (CS-682) in clinical trials
- SAR3419 in clinical trials
- Sargramostim (Leukine)
- Selumetinib (AZD6244) in clinical trials
- Semuloparin (AVE5026) in clinical trials
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tacrolimus (Prograf)
- Tamoxifen (Nolvadex)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tesetaxel (DJ-927) in clinical trials
- TH-302 in clinical trials
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Tigatuzumab (CS-1008) in clinical trials
- Tivantinib (ARQ 197) in clinical trials
- Tivozanib (AV-951) in clinical trials
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tosedostat in clinical trials
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (GSK1120212, JTP-74057) in clinical trials
- Trastuzumab (Herceptin)
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valacyclovir (Valtrex)
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Veliparib (ABT-888) in clinical trials
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) FDA approved 8/9/2012
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Volasertib (BI 6727) in clinical trials
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
W
Z
- Ziv-aflibercept (Zaltrap) FDA approved 8/3/2012
- Zoledronic acid (Zometa)
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article